| First Author | Tian Y | Year | 2021 |
| Journal | Front Aging Neurosci | Volume | 13 |
| Pages | 760781 | PubMed ID | 34744697 |
| Mgi Jnum | J:313970 | Mgi Id | MGI:6794127 |
| Doi | 10.3389/fnagi.2021.760781 | Citation | Tian Y, et al. (2021) Transgenic Mice Expressing Human alpha-Synuclein 1-103 Fragment as a Novel Model of Parkinson's Disease. Front Aging Neurosci 13:760781 |
| abstractText | Parkinson's disease (PD) is one of the most common neurodegenerative disorders. However, its cellular and molecular mechanisms still wrap in the mist. This is partially caused by the absence of appropriate animal models mimicking sporadic PD that constitutes the majority of cases. Previously, we reported that a cysteine protease, asparagine endopeptidase (AEP), is activated in an age-dependent manner, and cleaves alpha-synuclein in the brain of sporadic PD patients. The AEP-derived alpha-synuclein 1-103 fragment is required for the pathogenesis of PD. Thus, we designed and characterized a novel transgenic mouse line expressing alpha-synuclein 1-103 (designated N103 mice). This model shows an abundant accumulation of pathological alpha-synuclein in the central nervous system, loss of dopaminergic neurons in the substantia nigra, and progressive striatal synaptic degeneration. The N103 mice also manifest age-dependent PD-like behavioral impairments. Notably, the mice show weight loss and constipation, which are the common non-motor symptoms in PD. The RNA-sequencing analysis found that the transcriptomics pattern was extensively altered in N103 mice. In conclusion, the N103 mouse line, as a brand-new tool, might provide new insights into PD research. |
